Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$3.16
EPS est.
$0.39
EPS surprise
+706.12%
1-day move
+5.69%
Sarepta Therapeutics reported a significant earnings surprise on EPS, which drove the stock up by 5.69%. However, no revenue figures were provided, leaving some uncertainty. Investors may be encouraged by the strong EPS performance, but the lack of guidance and revenue details could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.16 | $1.05 | +706.12% |
| Revenue | — | $475M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD). With a market cap of $2 billion, its advancements in gene therapy and personalized medicine are significant in the healthcare sector.
Last quarter
In Q4 2025, Sarepta reported an EPS of -$3.58, significantly missing estimates. The stock reacted positively the next day, gaining 0.69%.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+47.13%
Avg 1-day reaction
-2.72%
Analysts are cautiously optimistic about Sarepta's upcoming earnings, expecting a rebound in EPS and revenue growth. However, the company has a history of mixed results, which adds uncertainty.
Bull case
If Sarepta can deliver better-than-expected earnings and show strong revenue growth, it could signal a turnaround and boost investor confidence.
Bear case
Conversely, if the company fails to meet expectations again, it could lead to further declines in stock price and investor sentiment.
Key metrics to watch
EPS
$1.05Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$475MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $1.05?
A positive surprise in EPS could indicate improved operational efficiency and boost investor confidence.
Q2
What is the revenue guidance for the upcoming quarters?
Understanding revenue trends will help assess the demand for Sarepta's therapies and overall market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for Sarepta to rebound, given its recent advancements in gene therapy.
Supporting evidence
Sarepta has a strong track record of beating EPS estimates, with a 75% beat rate over the last eight quarters.
The options market is pricing a larger move than historical averages, indicating heightened expectations.
Recent developments in their pipeline could lead to unexpected revenue growth.
Key risk
If the EPS comes in significantly above $1.05, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The market is watching Sarepta closely for signs of recovery after a series of disappointing earnings.
Bull confirmed if
Delivering EPS above $1.05 with revenue exceeding $475 million would confirm the bull case.
Bear confirmed if
Failing to meet the EPS estimate and showing declining revenue would confirm the bear case.
What the market is pricing for the move.
Implied Move
±9.3%
Historical Avg
±5.4%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.
Options are pricing ±9.4% while SRPT has averaged ±5.4% over the last 8 prints — setup is pricing rich.
ATM IV
1.3%
30d HV
103.6%
Smart-money positioning from the most recent 13F filings.
Institutional
104.10%
of float
Insider
4.89%
of float
Holders
442
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
18,994,958 sh · $332.4M
17.98%
28.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Sarepta beats expectations, history suggests a positive reaction of around +0.43%, confirming a turnaround narrative.
In line / cautious
An in-line report may lead to muted reactions as investors await further clarity on future guidance.
Miss
If the company misses expectations, the stock could drop by an average of -12.94%, reflecting ongoing concerns about its performance.
The lines on the call that would change the story.
State Street Corporation
8,916,090 sh · $156.0M
8.44%
34.8%
Vanguard Portfolio Management LLC
8,377,470 sh · $146.6M
7.93%
26.2%
Vanguard Capital Management LLC
4,591,755 sh · $80.4M
4.35%
0.3%
Two Sigma Investments, LP
4,598,735 sh · $80.5M
4.35%
0.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.